Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.

You may also be interested in...



Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA

Response to immunogenicity concern could boost chances for FDA approval next year.

Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA

Response to immunogenicity concern could boost chances for FDA approval next year.

Lovenox ANDA Approval In 2008 Is “Not Out Of Reach,” Momenta CEO Wheeler Says

Chief exec optimistic that FDA will not require any additional clinical trials to move filing forward.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS065455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By